07 February 2013
Non-small cell lung cancer evaluated with quantitative contrast-enhanced CT and PET-CT: Net enhancement and standardized uptake values are related to tumour size and histology
Luca BruneseAE, Barbara GrecoEF, Francesca Rosa SetolaEF, Francesco LassandroBD, Mario Rosario GuarracinoCD, Marialiusa De RiminiBD, Sergio PiccoloBD, Nicolina De RosaBD, Roberto MutoAG, Andrea BiancoAE, Pietro MutoAG, Roberto GrassiAG, Antonio RotondoAGDOI: 10.12659/MSM.883759
Med Sci Monit 2013; 19:95-101
Abstract
BACKGROUND: Personalized cancer therapy remains a challenge. In this context, we attempted to identify correlations between tumour angiogenesis, tumour metabolism and tumour cell type. To this aim, we used single=phase multidetector computed tomography (MDCT) and hybrid positron emission tomography-computed tomography (PET/CT) to determine whether net enhancement and standardized uptake value (SUVmax) were correlated with tumour size and cytology in patients affected by non-small cell lung cancer (NSCLC).
MATERIAL AND METHODS: Our study included 38 patients (30 men, 8 women, mean age 70) with a NSCLC measuring between 3 cm and 7 cm, using a 16-slice multidetector CT (Brilliance Philips) and with PET-CT (Biograph 16 Siemens Medical Solutions). The following lesion parameters were evaluated: maximum diameter, medium density before contrast injection (CTpre), medium density after contrast injection (CTpost average), density in the most enhanced part of the lesion after contrast (CTpost max), net enhancement, SUVmax, age, and cytology. Correlation coefficient and p-value were computed for each pair of variables. In addition, correlations were computed for each pair of variables, and for all combinations of tumour types. We focused on subsets of data with more than 10 observations, and with correlation r>0.500 and p<0.05.
RESULTS: A weak correlation (r=0.32; p=0.048) was found between SUVmax and tumour size; the correlation was stronger for masses larger than 31 mm (r=0.4515; p=0.0268). No other correlations were found among the variables examined.
CONCLUSIONS: Our data may have prognostic significance, and could lead to more appropriate surgical treatment and better treatment outcome.
Keywords: Positron-Emission Tomography, Lung Neoplasms - radionuclide imaging, Multimodal Imaging, Fluorodeoxyglucose F18 - pharmacokinetics, Contrast Media - diagnostic use, Carcinoma, Non-Small-Cell Lung - radionuclide imaging, Adenocarcinoma - radionuclide imaging, Tomography, X-Ray Computed, Tumor Burden
Editorial
01 January 2025 : Editorial
Editorial: The Human Cell Atlas. What Is It and Where Could It Take Us?DOI: 10.12659/MSM.947707
Med Sci Monit 2025; 31:e947707
In Press
Animal Research
Role of the Dorsal Cortex of the Inferior Colliculus in the Precedence EffectMed Sci Monit In Press; DOI: 10.12659/MSM.945605
Laboratory Research
Comparative Evaluation of the Dimensional Accuracy of Silicone-Based Putty Reline Impressions with Differen...Med Sci Monit In Press; DOI: 10.12659/MSM.946537
Clinical Research
Ankle-Brachial Index as a Predictor of Acute Ischemic Cerebrovascular Event After Central Retinal Artery Oc...Med Sci Monit In Press; DOI: 10.12659/MSM.945937
Review article
COL3A1 Gene Polymorphism and Its Impact on Female Pelvic Organ ProlapseMed Sci Monit In Press; DOI: 10.12659/MSM.946367
Most Viewed Current Articles
17 Jan 2024 : Review article 6,962,174
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 699,683
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 22,873
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 17,628
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912